Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

283 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Safety and Tolerability of MEDI0562, an OX40 Agonist mAb, in Combination with Durvalumab or Tremelimumab in Adult Patients with Advanced Solid Tumors.
Goldman JW, Piha-Paul SA, Curti B, Pedersen KS, Bauer TM, Groenland SL, Carvajal RD, Chhaya V, Kirby G, McGlinchey K, Hammond SA, Streicher K, Townsley DM, Chae YK, Voortman J, Marabelle A, Powderly J. Goldman JW, et al. Among authors: marabelle a. Clin Cancer Res. 2022 Sep 1;28(17):3709-3719. doi: 10.1158/1078-0432.CCR-21-3016. Clin Cancer Res. 2022. PMID: 35699623
Immune checkpoint modulation for non-small cell lung cancer.
Soria JC, Marabelle A, Brahmer JR, Gettinger S. Soria JC, et al. Among authors: marabelle a. Clin Cancer Res. 2015 May 15;21(10):2256-62. doi: 10.1158/1078-0432.CCR-14-2959. Clin Cancer Res. 2015. PMID: 25979932
Rationale for anti-OX40 cancer immunotherapy.
Aspeslagh S, Postel-Vinay S, Rusakiewicz S, Soria JC, Zitvogel L, Marabelle A. Aspeslagh S, et al. Among authors: marabelle a. Eur J Cancer. 2016 Jan;52:50-66. doi: 10.1016/j.ejca.2015.08.021. Epub 2015 Nov 30. Eur J Cancer. 2016. PMID: 26645943 Review.
Mutational Landscape and Sensitivity to Immune Checkpoint Blockers.
Chabanon RM, Pedrero M, Lefebvre C, Marabelle A, Soria JC, Postel-Vinay S. Chabanon RM, et al. Among authors: marabelle a. Clin Cancer Res. 2016 Sep 1;22(17):4309-21. doi: 10.1158/1078-0432.CCR-16-0903. Epub 2016 Jul 7. Clin Cancer Res. 2016. PMID: 27390348 Review.
A Phase I Study of the CDK4/6 Inhibitor Ribociclib (LEE011) in Pediatric Patients with Malignant Rhabdoid Tumors, Neuroblastoma, and Other Solid Tumors.
Geoerger B, Bourdeaut F, DuBois SG, Fischer M, Geller JI, Gottardo NG, Marabelle A, Pearson ADJ, Modak S, Cash T, Robinson GW, Motta M, Matano A, Bhansali SG, Dobson JR, Parasuraman S, Chi SN. Geoerger B, et al. Among authors: marabelle a. Clin Cancer Res. 2017 May 15;23(10):2433-2441. doi: 10.1158/1078-0432.CCR-16-2898. Epub 2017 Apr 21. Clin Cancer Res. 2017. PMID: 28432176 Clinical Trial.
Dose escalation results from a first-in-human, phase 1 study of glucocorticoid-induced TNF receptor-related protein agonist AMG 228 in patients with advanced solid tumors.
Tran B, Carvajal RD, Marabelle A, Patel SP, LoRusso PM, Rasmussen E, Juan G, Upreti VV, Beers C, Ngarmchamnanrith G, Schöffski P. Tran B, et al. Among authors: marabelle a. J Immunother Cancer. 2018 Sep 25;6(1):93. doi: 10.1186/s40425-018-0407-x. J Immunother Cancer. 2018. PMID: 30253804 Free PMC article. Clinical Trial.
Long-Term Survival in Patients Responding to Anti-PD-1/PD-L1 Therapy and Disease Outcome upon Treatment Discontinuation.
Gauci ML, Lanoy E, Champiat S, Caramella C, Ammari S, Aspeslagh S, Varga A, Baldini C, Bahleda R, Gazzah A, Michot JM, Postel-Vinay S, Angevin E, Ribrag V, Hollebecque A, Soria JC, Robert C, Massard C, Marabelle A. Gauci ML, et al. Among authors: marabelle a. Clin Cancer Res. 2019 Feb 1;25(3):946-956. doi: 10.1158/1078-0432.CCR-18-0793. Epub 2018 Oct 8. Clin Cancer Res. 2019. PMID: 30297458
283 results